Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical Study to Establish the Feasibility and Usability of the EndoRings

ABSTRACT: The purpose of this prospective clinical study is to establish the feasibility and usability of the ENDORINGS when used during standard colonoscopy procedure.

DISEASE(S): Bowel Cancer,Colon Cancer,Colorectal Cancer,Colorectal Neoplasms,Colonic Neoplasms

PROVIDER: 2145982 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

LC-HRMS Metabolomics for Untargeted Diagnostic Screening in Clinical Laboratories: A Feasibility Study

Project description:Today's high-resolution mass spectrometers (HRMS) allow bioanalysts to perform untargeted/global determinations that can reveal unexpected compounds or concentrations in a patient’s sample. This could be performed for preliminary diagnosis attempts when usual diagnostic processes and targeted determinations fail. We have evaluated an untargeted diagnostic screening (UDS) procedure. UDS is a metabolome analysis that compares one sample (e.g., a patient) with control samples (a healthy population). Using liquid chromatography (LC)-HRMS full-scan analysis of human serum extracts and unsupervised data treatment, we have compared individual samples that were spiked with one xenobiotic or a higher level of one endogenous compound with control samples. After the use of different filters that drastically reduced the number of metabolites detected, the spiked compound was eventually revealed in each test sample and ranked. The proposed UDS procedure appears feasible and reliable to reveal unexpected xenobiotics (toxicology) or higher concentrations of endogenous metabolites. HRMS-based untargeted approaches could be useful as preliminary diagnostic screening when canonical processes do not reveal disease etiology nor establish a clear diagnosis and could reduce misdiagnosis. On the other hand, the risk of overdiagnosis of this approach should be reduced with mandatory biomedical interpretation of the patient’s UDS results and with confirmatory targeted and quantitative determinations.

2019-06-06 | MTBLS476 | MetaboLights

On the feasibility of clinical studies with cross-linking mass spectrometry

Project description:In living systems, protein function relies on many interactions within a network called the interactome. The majority of available interactome data has been acquired with isolated proteins and complexes, but understanding interactome changes in living systems is crucial to advance understanding of functional changes with diseases and for development of improved therapies. With model animal systems, quantitative cross-linking mass spectrometry has been successfully applied to uniquely mitochondrial interactome changes with mitochondrial dysfunction both in heart failure and with age-related muscle function decline. In this study, we investigated the feasibility of qualitative cross-linking mass spectrometry for mitochondrial interactome studies with clinically-relevant human muscle biopsy samples and amounts. By analyzing biopsy samples from two volunteers, 3175 unique peptides from 322 mitochondrial proteins were identified from all mitochondrial subcompartments. Many of the identified human biopsy cross-linked peptides were derived from protein complex and supercomplex assemblies that exhibited altered levels in model systems of heart failure and aging. The findings demonstrate the initial feasibility that these and other cross-linked species can be detected in human muscle biopsy samples to enable future studies of age- and disease-related changes in mitochondrial structure-function relationships.

2025-09-26 | PXD068129 | Pride

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Project description:The aims of this study were to assess the feasibility of prospective pharmacogenomics research in multicenter international clinical trials of bortezomib in multiple myeloma and to develop predictive classifiers of response and survival with bortezomib. Patients with relapsed myeloma enrolled in phase 2 and phase 3 clinical trials of bortezomib and consented to genomic analyses of pretreatment tumor samples. Bone marrow aspirates were subject to a negative-selection procedure to enrich for tumor cells, and these samples were used for gene expression profiling using DNA microarrays. Data quality and correlations with trial outcomes were assessed by multiple groups. Gene expression in this dataset was consistent with data published from a single-center study of newly diagnosed multiple myeloma. Response and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data. The survival classifier improved on the risk stratification provided by the International Staging System. Predictive models and biologic correlates of response show some specificity for bortezomib rather than dexamethasone. Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents. Keywords: Gene expression profiling; correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

2007-12-06 | GSE9782 | GEO

Blood Gene Expression Profiling in Colorectal Cancer

Project description:In this work, we performed gene expression profiling for twenty-paired blood samples collected from healthy controls before and after colonoscopy, and twenty blood samples collected from<br>colorectal cancer patients after colonoscopy. The aim of this study is to determine how significant the colonoscopy procedure may impact the global gene expression in human peripheral blood, and whether this colonoscopy induced variability would bias the biomarker research for colorectal cancer early detection.

2013-10-01 | E-MEXP-3756 | biostudies-arrayexpress

Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience

Project description:Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience

| PRJNA1180454 | ENA

Feasibility Study of a Novel Single Use Robotic Colonoscopy System

Project description:This is a single centre, non-randomized, tandem colonoscopy trial of the NISInspire-C System, followed immediately by a conventional colonoscope (CC). Each trial subject will undergo colonoscopy using the NISInspire-C system, followed immediately by CC. The purpose of this study is to obtain observational data on the safety profile, feasibility and usability of the NISInspire-C System in performing diagnostic colonoscopy in human subjects. The level of procedural pain experienced by subjects will also be explored.

| 2307836 | ecrin-mdr-crc

Feasibility of Circulating 5-hydroxymethylcytosine profiling in Osteosarcoma

Project description:Feasibility of Circulating 5-hydroxymethylcytosine profiling in Osteosarcoma

| PRJNA1187684 | ENA

Feasibility of Circulating 5-hydroxymethylcytosine profiling in Osteosarcoma

Project description:Feasibility of Circulating 5-hydroxymethylcytosine profiling in Osteosarcoma

| PRJNA1187685 | ENA

A 4-arm Clinical Trial of Fuse, EndoCuff, EndoRings and Standard Colonoscopy

Project description:Adenoma detection rate (ADR) is a validated marker for reducing the risk of interval colorectal cancer after a screening colonoscopy. Recent studies suggest that novel devices attached to the colonoscope tip may improve the ADR of doctors performing a screening procedure

| 2182492 | ecrin-mdr-crc

Feasibility and clinical utility of whole genome profiling in pediatric and young adult cancers

Project description:Feasibility and clinical utility of whole genome profiling in pediatric and young adult cancers

| PRJNA766101 | ENA